Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

Companies Resolve Lawsuit in Delaware

Mar. 16, 2026 at 11:55am

Got story updates? Submit your updates here. ›

Zevra Therapeutics, a commercial-stage company focused on rare disease therapies, has announced an agreement to sell its serdexmethylphenidate (SDX) portfolio, including AZSTARYS and KP1077, to Commave Therapeutics SA for $50 million. The companies had previously entered into a 2019 licensing agreement, and Commave had initiated litigation against Zevra in 2024. As part of the new purchase agreement, the parties have agreed to settle the dispute.

Why it matters

The sale of the SDX portfolio allows Zevra to focus on its core mission of developing therapies for rare diseases, while Commave, which already had a licensing agreement for the SDX products, will now fully control the portfolio. The resolution of the lawsuit between the companies also provides clarity and closure on this aspect of their relationship.

The details

Under the agreement, Commave will purchase Zevra's entire SDX portfolio, including AZSTARYS and KP1077. Prior to the sale, Zevra repaid the $63 million principal balance on its term loan, leaving the company with a strong, debt-free balance sheet and enhanced financial and strategic flexibility to pursue its next chapter.

  • Zevra and Commave entered into a 2019 license agreement.
  • In 2024, Commave initiated litigation against Zevra in Delaware Chancery Court.
  • The new purchase agreement and settlement of the lawsuit was announced on March 16, 2026.

The players

Zevra Therapeutics, Inc.

A commercial-stage company focused on providing therapies for people living with rare disease.

Commave Therapeutics SA

The company that is purchasing Zevra's serdexmethylphenidate (SDX) portfolio, including AZSTARYS and KP1077.

Neil F. McFarlane

Zevra's President and Chief Executive Officer.

Got photos? Submit your photos here. ›

What they’re saying

“We are pleased to have reached a mutually beneficial agreement with Commave regarding the sale of our entire SDX portfolio. Over the years, we have enjoyed a productive partnership with Commave, and we are confident these programs are in capable hands. We are excited to turn the page to Zevra's next chapter and remain focused on our mission of redefining what's possible for patients living with rare diseases.”

— Neil F. McFarlane, Zevra's President and Chief Executive Officer (Globe Newswire)

What’s next

The judge in the Delaware Chancery Court case will approve the settlement between Zevra and Commave as part of the purchase agreement.

The takeaway

This transaction allows Zevra to focus on its core mission of developing rare disease therapies, while Commave, which already had a licensing agreement for the SDX products, will now fully control the portfolio. The resolution of the lawsuit between the companies also provides clarity and closure on this aspect of their relationship.